NEws & Insights

The US/UK pharma trade deal doesn’t change everything, but it does shift the landscape launch and access teams are working within. One practical part of the deal is that medicines made in the UK can now be exported to the US without tariffs, at least for the next few years. That doesn’t suddenly make US launches easier, but it does remove one awkward unknown from pricing and supply planning. When teams are already juggling timelines, uptake assumptions and internal pressure,

There’s an uncomfortable truth in pharma right now. In 2025, you can do everything right.. and still hear “no”. You can have strong efficacy data, a clean safety profile, a clearly defined unmet need, and respected KOLs genuinely excited about the product. On paper, it looks like a success story waiting to happen. Yet without payer buy in, that momentum can disappear very quickly. No reimbursement means no real launch. No launch means limited uptake.. and ultimately, patients